CARVEDILOL AS A POTENTIAL ADDITION TO THE COVID-19 THERAPEUTIC ARSENAL

  • NAKHLE AYOUB MD. Hôtel Dieu de France Hospital, Dermatology Department, Beirut, Lebanon, Holy Spirit University, Kaslik, Lebanon

Abstract

No single therapeutic agent has been recognized so far as the ultimate treatment for COVID-19 and many treatment strategies rely on associating different medications with proven or hypothetical anti-viral effects. Carvedilol is a third-generation beta-blocker displaying potential inhibitory properties on several key enzymatic processes and pathways involved in SARS-CoV-2 or other coronaviruses replication, in addition to the modulatory effect on several inflammatory messengers of COVID-19. These data could provide a reasonable hypothetical background for further investigating specific anti-SARS-CoV-2 effects and could pave the way for further clinical verification.

Keywords: Carvedilol, SARS-CoV-2, COVID-19

Downloads

Download data is not yet available.

References

1. Ma Z, Liu X, Zhang Q, Yu Z, Gao D. Carvedilol suppresses malignant proliferation of mammary epithelial cells through inhibition of the ROS?mediated PI3K/AKT signaling pathway. Oncol Rep 2019;41:811-8.
2. Liu B, Liu YJ. Carvedilol promotes retinal ganglion cell survival following optic nerve injury via ASK1-p38 MAPK pathway. CNS Neurol Disord: Drug Targets 2019;18:695-704.
3. Zawadzka K, Nowak M, Piwonski I, Lisowska K. The synergy of ciprofloxacin and carvedilol against staphylococcus aureus-prospects of a new treatment strategy? Molecules 2019;24:4104.
4. Kurum T, Tatli E, Yuksel M. Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy. Cardiovasc Dis 2007;34:52–9.
5. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the anti-viral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020;105938. http://doi:10.1016/j.ijantimicag.2020.105938.
6. Saijonmaa O, Nyman T, Fyhrquist F. Carvedilol inhibits basal and stimulated ACE production in human endothelial cells. J Cardiovasc Pharmacol 2004;43:616-21.
7. Meng D, Li Z, Wang G, Ling L, Wu Y, Zhang C. Carvedilol attenuates liver fibrosis by suppressing autophagy and promoting apoptosis in hepatic stellate cells. Biomed Pharmacother 2018;108:1617-27.
8. Banerjee S, Narayanan K, Mizutani T, Makino S. Murine coronavirus replication-induced p38 mitogen-activated protein kinase activation promotes interleukin-6 production and virus replication in cultured cells. J Virol 2002;76:5937-48.
9. Park J, Ha H, Kim MS, Ahn HJ, Huh KH, Kim YS. Carvedilol inhibits platelet-derived growth factor-induced extracellular matrix synthesis by inhibiting cellular reactive oxygen species and mitogen-activated protein kinase activation. J Heart Lung Transplant 2006;25:683-9.
10. Kalinowski L, Dobrucki LW, Szczepanska Konkel M, Jankowski M, Martyniec L, Angielski S, et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003;107:2747-52.
11. Akerstrom S, Mousavi Jazi M, Klingstrom J, Leijon M, Lundkvist A, Mirazimi A. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol 2005;79:1966-9.
12. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharma Sin B 2020. https://doi.org/10.1016/j.apsb.2020.02.008
13. Nash CA, Wei W, Irannejad R, Smrcka AV. Golgi localized ?1-adrenergic receptors stimulate Golgi PI4P hydrolysis by PLC? to regulate cardiac hypertrophy. Elife 2019;8:e48167. https://doi:10.7554/eLife.48167
14. Yang Z, Kirton HM, MacDougall DA, Boyle JP, Deuchars J, Frater B, et al. The Golgi apparatus is a functionally distinct Ca2+store regulated by the PKA and Epac branches of the ?1-adrenergic signaling pathway. Sci Signal 2015;8:ra101.
15. Brignoni M, Pignataro OP, Rodriguez ML, Alvarez A, Vega Salas DE, Rodriguez-Boulan E, et al. Cyclic AMP modulates the rate of 'constitutive' exocytosis of apical membrane proteins in Madin-Darby canine kidney cells. J Cell Sci 1995;108:1931-43.
16. Xiaohua C, Binghong Z, Yueming Q, Yurou C, Jie X, Yong F, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. medRxiv 2020. https://doi.org/10.1101/2020.02.29.20029520
17. Herold T, Jurinovic V, Arnreich C, Hellmuth JC, Von Bergwelt-Baildon M, Klein M, et al. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. medRxiv 2020. https://doi.org/10.1101/2020.04.01.20047381
18. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci Chin Life Sci 2020;63:364-74.
19. DeDiego ML, Nieto Torres JL, Regla Nava JA, Jimenez Guardeno JM, Fernandez-Delgado R, et al. Inhibition of NF-?B-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol 2014;88:913-24.
20. Yang SP, Ho LJ, Lin YL, Cheng SM, Tsao TP, Chang DM, Hsu YL, et al. Carvedilol, a new antioxidative beta-blocker, blocks in vitro human peripheral blood T cell activation by downregulating NF-kappa B activity. Cardiovasc Res 2003;59:776-87.
21. Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999;12:451-9.
22. Baglivo M, Baronio M, Natalini G, Beccari T, Chiurazzi P, Fulcheri E, et al. Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity? Acta Biomed 2020;91:161-4.
23. Pratelli A, Colao V. Role of the lipid rafts in the life cycle of canine coronavirus. J Gen Virol 2015;96:331-7.
24. Glende J, Schwegmann Wessels C, Al-Falah M, Pfefferle S, Qu X, Deng H, et al. Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2. Virology 2008;381:215–21.
25. Wen X, Tan F, Jing Z, Liu Z. Preparation and study the 1:2 inclusion complex of carvedilol with beta-cyclodextrin. J Pharm Biomed Anal 2004;34:517-23.
26. CK Oh Assignee, Smith Kline Beecham. Novel formulations of carvedilol. Patent No: WO03028649; 2003.
27. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Anti-viral Res 2020. https://doi.org/10.1016/ j.antiviral.2020.104787.
Statistics
612 Views | 206 Downloads
Citatons
How to Cite
MD., N. A. “CARVEDILOL AS A POTENTIAL ADDITION TO THE COVID-19 THERAPEUTIC ARSENAL”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 12, no. 6, May 2020, pp. 87-89, doi:10.22159/ijpps.2020v12i6.38057.
Section
Hypothesis